Isomorphic Labs
Alphabet-backed AI drug design company spun out of Google DeepMind, building the IsoDDE discovery engine.
- Biotech & Life Sciences
- Series B+
- London
- Sector
- Biotech & Life Sciences
- Stage
- Series B+
- Based in
- London
- Founded
- 2021
- Funding raised
- $2.7B
- Website
- isomorphiclabs.com
Isomorphic Labs applies AI to drug design, building on the AlphaFold lineage from Google DeepMind, from which it was spun out in 2021. Its IsoDDE engine models how molecules interact with protein targets in order to design candidate medicines faster than traditional discovery methods, and the company runs partnered programmes with large pharmaceutical groups alongside an internal pipeline. Headquartered in London with offices in Cambridge, Massachusetts and Lausanne, it announced a $2.1bn Series B in May 2026 led by Thrive Capital, with Alphabet, GV, MGX, Temasek, CapitalG and the UK Sovereign AI Fund participating. The company has said it aims to move its first candidates into clinical trials.
Team
- Demis Hassabis, Founder & CEO
- Max Jaderberg, President
Backed by
More startups in the directory
Fyxer
AI executive assistant that organises inboxes, drafts email replies and takes meeting notes.
Flo Health
Women's health app for period, cycle and pregnancy tracking with nearly 70m monthly users.
9fin
AI-native data and analytics platform for the global debt capital markets.
Zopa
Peer-to-peer lending pioneer turned licensed digital bank with over 2 million customers.
Tide
Business banking and admin platform for SMEs, serving over 2 million members in the UK, India and Europe.
Thought Machine
Cloud-native core banking platform (Vault) used by tier-one banks and challengers worldwide.
Subscribe to Newsletter
UK startup news, founder stories and funding insight, straight to your inbox every week. Free.